ASH 2021 Focus on GVHD for Pharmacists

Advertisement
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 24, 2023
Patients with hematologic malignancies who may require blood transfusions may not be able to enroll in hospice care ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 24, 2023
Updated results from a real-world analysis confirm that ruxolitinib is an effective treatment option for patients with ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | August 25, 2023
Prophylactic treatment with subcutaneous fitusiran administered once-monthly reduced bleeding risk in patients with ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 24, 2023
According to a poster presented at the 2021 ASH Annual Meeting by Maria Queralt Salas, MD, from the Hospital Clinic of ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | July 5, 2023
The combination of daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 24, 2023
Prescribing chemotherapy is not a universal practice of advanced practice providers (APPs) in the oncology community, ...
Advertisement